Illumina opened an early access program for a duplex sequencing workflow aimed at molecular residual disease and tumor evolution research. The research-use-only approach is designed to detect extremely low ctDNA fractions by confirming variants with both complementary strands, improving confidence that signals represent biology rather than library or sequencing artifacts. The workflow pairs a NovaSeq X sequencing platform with DRAGEN bioinformatics and supports 5–10 ng of cfDNA input. Illumina says representative studies detect ctDNA at 2.5 parts per million, with kits expected to ship in Q1 2027; NYU Langone Health is listed among early access users.